Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Joint EHA and national society membership

Enjoy the best of both worlds—and save money—by combining an EHA membership with membership of your national hematology society. This special type of membership package is the result of our constructive collaborations with a range of national hematology societies.

Read more

EHA Congratulates EHA Kick-Off Grant 2021 Winners

The Hague, January 3, 2022  –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

 

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Read more

EHA pays tribute to Professor Jacques-Louis Binet (1932–2024)

We would like to pause to acknowledge the passing of Professor Jacques-Louis Binet, a pioneer in clinical and biological research and an exceptional personality in hematology, on December 17, 2024.

Read more

Burnouts: when caregivers become patients

Author: Côme Bommier (Young EHA Ambassador)
Affiliations: Hôpital St-Louis (Paris, France) & Mayo Clinic (Rochester MN, USA)

A survey will be released in September to further map burnout
among hematology professionals in Europe.

Read more